NDC-11 (Package) | NDC-9 (Product) | Generic Name | Brand Name | Strength | SEER*Rx Category | Major Class | Minor Class | Administration Route | Package Effective Date | Package Discontinuation Date | Status |
---|---|---|---|---|---|---|---|---|---|---|---|
50742-0184-25 | 50742-0184 | Leucovorin Calcium | Leucovorin Calcium | 25.0 mg/1 | Ancillary Therapy | Chemoprotective | Antidote | Oral | Jul 30, 2020 | In Use | |
50742-0519-02 | 50742-0519 | cyclophosphamide | CYCLOPHOSPHAMIDE | 200.0 mg/mL | Chemotherapy | Alkylating Agent | Nitrogen Mustard | Intravenous | Jul 30, 2020 | Mar 30, 2025 | In Use |
50742-0520-05 | 50742-0520 | cyclophosphamide | CYCLOPHOSPHAMIDE | 200.0 mg/mL | Chemotherapy | Alkylating Agent | Nitrogen Mustard | Intravenous | Jul 30, 2020 | Mar 30, 2025 | In Use |
50742-0181-30 | 50742-0181 | Leucovorin Calcium | Leucovorin Calcium | 5.0 mg/1 | Ancillary Therapy | Chemoprotective | Antidote | Oral | Jul 30, 2020 | In Use | |
50742-0182-12 | 50742-0182 | Leucovorin Calcium | Leucovorin Calcium | 10.0 mg/1 | Ancillary Therapy | Chemoprotective | Antidote | Oral | Jul 30, 2020 | In Use | |
55150-0386-00 | 55150-0386 | CARBOPLATIN | CARBOPLATIN | 600.0 mg/60mL | Chemotherapy | Alkylating Agent | Platinum Compound | Intravenous | Aug 3, 2020 | In Use | |
70255-0025-06 | 70255-0025 | Encorafenib | BRAFTOVI | 75.0 mg/1 | Chemotherapy | BRAF Inhibitor | V600E | Oral | Aug 3, 2020 | In Use | |
55150-0386-01 | 55150-0386 | CARBOPLATIN | CARBOPLATIN | 600.0 mg/60mL | Chemotherapy | Alkylating Agent | Platinum Compound | Intravenous | Aug 3, 2020 | In Use | |
70255-0025-05 | 70255-0025 | Encorafenib | BRAFTOVI | 75.0 mg/1 | Chemotherapy | BRAF Inhibitor | V600E | Oral | Aug 3, 2020 | In Use | |
00469-0625-99 | 00469-0625 | enzalutamide | Xtandi | 40.0 mg/1 | Hormonal Therapy | Androgen Receptor Inhibitor | Non-Steroidal | Oral | Aug 4, 2020 | In Use | |
00469-0725-60 | 00469-0725 | enzalutamide | Xtandi | 80.0 mg/1 | Hormonal Therapy | Androgen Receptor Inhibitor | Non-Steroidal | Oral | Aug 4, 2020 | In Use | |
00469-1725-56 | 00469-1725 | Enzalutamide | Xtandi | 40.0 mg/1 | Hormonal Therapy | Androgen Receptor Inhibitor | Non-Steroidal | Oral | Aug 4, 2020 | In Use | |
75929-0787-36 | 75929-0787 | Tafasitamab-cxix | MONJUVI | 200.0 mg/5mL | Immunotherapy | Monoclonal Antibody | CD19 | Intravenous | Aug 5, 2020 | In Use | |
00173-0896-01 | 00173-0896 | Belantamab | Blenrep | 50.0 mg/mL | Immunotherapy | Drug Antibody Conjugate | BCMA | Intravenous | Aug 5, 2020 | Jun 30, 2024 | No Longer Used |
73535-0208-01 | 73535-0208 | Tafasitamab-cxix | MONJUVI | 200.0 mg/5mL | Immunotherapy | Monoclonal Antibody | CD19 | Intravenous | Aug 5, 2020 | In Use | |
50881-0013-01 | 50881-0013 | Tafasitamab-cxix | MONJUVI | 200.0 mg/5mL | Immunotherapy | Monoclonal Antibody | CD19 | Intravenous | Aug 5, 2020 | Jan 30, 2025 | In Use |
50881-0013-03 | 50881-0013 | Tafasitamab-cxix | MONJUVI | 200.0 mg/5mL | Immunotherapy | Monoclonal Antibody | CD19 | Intravenous | Aug 5, 2020 | In Use | |
10019-0984-01 | 10019-0984 | Cyclophosphamide | Cyclophosphamide | 50.0 mg/1 | Chemotherapy | Alkylating Agent | Nitrogen Mustard | Oral | Aug 7, 2020 | In Use | |
10019-0982-01 | 10019-0982 | Cyclophosphamide | Cyclophosphamide | 25.0 mg/1 | Chemotherapy | Alkylating Agent | Nitrogen Mustard | Oral | Aug 7, 2020 | In Use | |
70518-2829-00 | 70518-2829 | Estradiol | Estradiol | 2.0 mg/1 | Hormonal Therapy | Estrogen | Oral | Aug 7, 2020 | In Use | ||
70934-0580-20 | 70934-0580 | Prednisone | Prednisone | 10.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | Aug 11, 2020 | In Use | |
71205-0403-07 | 71205-0403 | Prednisone | Prednisone | 20.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | Aug 13, 2020 | Aug 31, 2023 | No Longer Used |
59651-0299-60 | 59651-0299 | Tamoxifen Citrate | Tamoxifen Citrate | 10.0 mg/1 | Hormonal Therapy | Selective Estrogen Receptor Modulator (SERM) | Oral | Aug 14, 2020 | In Use | ||
59651-0300-90 | 59651-0300 | Tamoxifen Citrate | Tamoxifen Citrate | 20.0 mg/1 | Hormonal Therapy | Selective Estrogen Receptor Modulator (SERM) | Oral | Aug 14, 2020 | In Use | ||
59651-0300-30 | 59651-0300 | Tamoxifen Citrate | Tamoxifen Citrate | 20.0 mg/1 | Hormonal Therapy | Selective Estrogen Receptor Modulator (SERM) | Oral | Aug 14, 2020 | In Use |
Found 11398 results — Export these results